P. Kumar

Assessment of intravenous pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) in yucatan swine

F. Clubb, D. Rao, N. Senzer, 2013, Cancer Gene Therapy.

Proof concept for clinical justification of network mapping for personalized cancer therapeutics

I. Khalil, C. Hill, D. Rao, 2007, Cancer Gene Therapy.

Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference

D. Rao, N. Senzer, J. Nemunaitis, 2010, Cancer Gene Therapy.

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

N. Senzer, J. Nemunaitis, B. Pappen, 2009, Cancer Gene Therapy.

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

R. Kratzke, Priya Kumar, A. Dudek, 2009, British Journal of Cancer.

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

P. LoRusso, G. Schwartz, M. Gounder, 2020 .